Minimum clinical important difference for resilience scale specific to cancer: a prospective analysis.

Xiao Ming QuanZhang ZhangYing TangJian LiangXiao Ying ZhangGuang Yun HuZhe SunMu Zi LiangYuan Liang Yu

Published in: Health and quality of life outcomes (2020)

The most reliable MCID is around 5 points for RS-SC-25 and 2 points for RS-SC-10. RS-SCs are more responsive to the worsening status of resilience in patients with cancer and these estimates could be useful in future resilience-based intervention trials.

Keyphrases

climate change
social support
randomized controlled trial
papillary thyroid
current status
cancer therapy
depressive symptoms
squamous cell carcinoma
squamous cell
drug delivery
young adults
lymph node metastasis
childhood cancer